Claritev - Class A opened higher at $28.25, compared with its previous close of $28.21. In the last trading session, the stock traded between $25.92 and $28.92. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Claritev - Class A is now worth
$ 128.81
Giving a profit of
$ 28.81 (28.81%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
$-1.17 (-4.15%)
Day High
$28.92
Day Low
$25.92
Day Open
$28.25
Prev Close
$28.21
Volume
1,89,504
1W Return
24.88%
1M Return
11.15%
3M Return
-22.74%
6M Return
-8.81%
1Y Return
-52.77%
Fundamentals
Market Cap ($ Mn)
462
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
0.36%
EPS (TTM)
$-3.62
Investment Returns
1 Week
24.88%
1 Month
11.15%
3 Months
-22.74%
6 Months
-8.81%
9 Months
29.99%
Financials
Quarterly
All values in $ Mn
241.6
Jun 25
246.0
Sep 25
246.6
Dec 25
244.7
Mar 26
257.5
Jun 26
268.3
Sep 26
Updates
9Nov
Claritev Q3FY26 Results: Revenue up 9.1%, guidance beats estimate
Revenue rose 9.1% YoY to $268.3 million in Q3FY26. EPS of $(3.64) beat consensus estimate of $(3.81). FY26 revenue guidance raised to $1.038B-$1.043B vs $1.014B estimate. Adjusted EBITDA margin contracted 270 bps to 60.4%.
Claritev publishes 2025 Corporate Responsibility Report focusing on AI governance and sustainability. Appoints first Head of Responsible AI and joins Coalition for Health AI. Launches Claritev Cares Foundation to improve healthcare access and equity. Retains Great Place To Work Certification for fourth consecutive year.
1mo ago
17Aug
Claritev expands partnership with Marpai for health plan integrity services
Claritev Corporation and Marpai Inc have deepened their strategic alliance to deliver end-to-end payment integrity solutions. The deal integrates Claritev's technology into Marpai's health plan administration services, covering both pre- and post-payment phases to enhance operational efficiency and accuracy for clients.
2mo ago
7Aug
Claritev raises FY26 sales guidance to $1.02B vs $993.5M estimate
Claritev Corporation reports Q2 EPS of $(3.49) beating estimates, with revenues at $257.5M. Full-year 2026 guidance is raised to $1.000B-$1.020B, surpassing the $993.511M consensus, driven by strong TPA bookings and improved free cash flow.
3mo ago
21Jul
Canaccord Genuity raises Claritev price target to $37
Canaccord Genuity analyst Richard Close maintained a Buy rating on Claritev (NYSE: CTEV) and increased the price target to $37 from $32.
3mo ago
16Jul
Claritev Corporation to announce Q2FY26 results on August 7
Claritev Corporation will release its Q2FY26 financial results on August 7, 2026, followed by a conference call at 8:00 am ET. Investors can access the live webcast via the company's website or join by phone.
